Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Siltuximab (Primary)
- Indications Cytokine release syndrome; Hepatitis B; Hepatitis C; Non-Hodgkin's lymphoma
- Focus Adverse reactions
Most Recent Events
- 31 Jan 2025 Status changed from active, no longer recruiting to completed.
- 28 May 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned initiation date changed from 1 Jan 2023 to 1 Feb 2023.